Reuters logo
BRIEF-Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of FATE-NK100
2017年11月10日 / 下午1点14分 / 12 天前

BRIEF-Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of FATE-NK100

Nov 10 (Reuters) - Fate Therapeutics Inc

* Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of Fate-NK100 for relapsed / refractory acute myelogenous leukemia at SITC 2017 annual meeting

* Fate Therapeutics Inc - ‍ Anti-leukemia activity was observed with FATE-NK100 in each of treated dose cohorts of voyage study​

* Fate Therapeutics - ‍ “Disappearance of all cells with morphologic characteristics of leukemia validates in vivo anti-leukemia activity of FATE-NK100”​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below